Literature DB >> 2488698

Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7).

P Guillaud1, S du Manoir, D Seigneurin.   

Abstract

The expression of a human nuclear antigen associated with cell proliferation and recognized by monoclonal antibody Ki-67 was investigated during the cell cycle in a breast cancer cell line (MCF-7) and in a normal human fibroblastic cell line (MRC-5). Image cytometry was used to determine Ki-67 antigen and DNA amounts at the cell level. Results confirm Ki-67 antibody specificity for proliferating cells. The antigen expression increases with cell progression through the cycle. Image cytometry also permits the description of the Ki-67 topographic distribution at the various phases of the cell cycle. Ki-67 antigen is essentially localized in the nucleoli at G1 phase. A nucleoplasmic distribution appears later in the cell cycle. The parameters measured on the labelling allow the calculation of the growth fraction and an evaluation of the phase fractions. Other results in this study strongly suggest that nucleolar rRNA synthesis is required for Ki-67 antigen expression. Hypotheses on Ki-67 functions are proposed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2488698

Source DB:  PubMed          Journal:  Anal Cell Pathol        ISSN: 0921-8912            Impact factor:   2.916


  13 in total

Review 1.  Proliferation markers in tumours: interpretation and clinical value.

Authors:  P J van Diest; G Brugal; J P Baak
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

Review 2.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

3.  Monoclonal antibody JC1: new reagent for studying cell proliferation.

Authors:  M C Garrido; J L Cordell; M H Becker; G Key; J Gerdes; M Jones; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

4.  Proliferation in Adrenocortical Tumors: Correlation with Clinical Outcome and p53 Status.

Authors:  Anne M. McNicol; Andrew L. Struthers; Claire E. Nolan; Jo Hermans; Harm R. Haak
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

5.  Evaluation of proliferation parameters in in vivo bromodeoxyuridine labelled lung cancers.

Authors:  M M Tinnemans; M H Lenders; G P ten Velde; S S Wagenaar; G H Blijham; F C Ramaekers; B Schutte
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

7.  The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.

Authors:  C Schlüter; M Duchrow; C Wohlenberg; M H Becker; G Key; H D Flad; J Gerdes
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

8.  The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study.

Authors:  Maysam Alimohamadi; Vahid Ownagh; Leila Mahouzi; Afshin Ostovar; Kazem Abbassioun; Abbas Amirjmshidi
Journal:  Asian J Neurosurg       Date:  2014 Jul-Sep

9.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  Cellular profile of the peritumoral inflammatory infiltrate in squamous cells carcinoma of oral mucosa: Correlation with the expression of Ki67 and histologic grading.

Authors:  Fabricio L D Vieira; Beatriz J Vieira; Marco A M Guimaraes; Fernando M Aarestrup
Journal:  BMC Oral Health       Date:  2008-09-02       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.